Original Research
Published on 18 Jun 2025
The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection
in Cancer Immunity and Immunotherapy
- 162 views